Abstract

The accurate prediction of the binding affinity changes of drugs caused by protein mutations is a major goal in clinical personalized medicine. We have developed an ensemble-based free energy approach called thermodynamic integration with enhanced sampling (TIES), which yields accurate, precise, and reproducible binding affinities. TIES has been shown to perform well for predictions of free energy differences of congeneric ligands to a wide range of target proteins. We have recently introduced variants of TIES, which incorporate the enhanced sampling technique REST2 (replica exchange with solute tempering) and the free energy estimator MBAR (Bennett acceptance ratio). Here we further extend the TIES methodology to study relative binding affinities caused by protein mutations when bound to a ligand, a variant which we call TIES-PM. We apply TIES-PM to fibroblast growth factor receptor 3 (FGFR3) to investigate binding free energy changes upon protein mutations. The results show that TIES-PM with REST2 successfully captures a large conformational change and generates correct free energy differences caused by a gatekeeper mutation located in the binding pocket. Simulations without REST2 fail to overcome the energy barrier between the conformations, and hence the results are highly sensitive to the initial structures. We also discuss situations where REST2 does not improve the accuracy of predictions.

Highlights

  • Mutations enable proteins to tailor molecular recognition with small-molecule ligands and other macromolecules, and can have a major impact on drug efficacy

  • Some significant improvements are observed from thermodynamic integration with enhanced sampling (TIES)-λ-REST2 simulations, while the inclusion of multistate Bennett acceptance ratio (MBAR) only slightly improves the accuracy and precision (Table 1)

  • We mainly focus on the comparisons of TIES and TIES-λ-REST2

Read more

Summary

Introduction

Mutations enable proteins to tailor molecular recognition with small-molecule ligands and other macromolecules, and can have a major impact on drug efficacy. The use of targeted therapeutics will benefit cancer patients by matching their genetic profile to the most effective drugs available Examples of such drugs are gefitinib and erlotinib which belong to a class of targeted cancer drugs called tyrosine kinase inhibitors. A subgroup of patients with nonsmall-cell lung cancer (NSCLC) have specific point mutations and deletions in the kinase domain of epidermal growth factor receptor (EGFR), which are associated with gefitinib and erlotinib sensitivity. Screening for these mutations may identify patients who will have a better response to certain inhibitors

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call